Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchiectasis | 5 | 2023 | 7 | 3.550 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 8 | 2023 | 12 | 3.230 |
Why?
|
| Lung Diseases | 5 | 2023 | 40 | 2.990 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 3 | 2023 | 3 | 1.720 |
Why?
|
| Mycobacterium avium Complex | 4 | 2023 | 4 | 1.330 |
Why?
|
| Medicare | 4 | 2023 | 197 | 1.230 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2026 | 540 | 1.210 |
Why?
|
| Nontuberculous Mycobacteria | 5 | 2023 | 7 | 1.130 |
Why?
|
| Aged | 21 | 2026 | 6223 | 1.080 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 152 | 1.070 |
Why?
|
| Humans | 39 | 2026 | 17622 | 1.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2023 | 104 | 1.020 |
Why?
|
| Latent Tuberculosis | 1 | 2026 | 14 | 0.940 |
Why?
|
| Hospitalization | 4 | 2026 | 831 | 0.930 |
Why?
|
| Vaccination | 7 | 2025 | 726 | 0.890 |
Why?
|
| Retrospective Studies | 14 | 2026 | 2502 | 0.860 |
Why?
|
| Influenza Vaccines | 2 | 2024 | 301 | 0.850 |
Why?
|
| Influenza, Human | 2 | 2024 | 294 | 0.850 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 1976 | 0.840 |
Why?
|
| Graft Rejection | 1 | 2024 | 3 | 0.840 |
Why?
|
| Male | 23 | 2026 | 10014 | 0.830 |
Why?
|
| United States | 10 | 2024 | 3922 | 0.810 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 208 | 0.800 |
Why?
|
| Rifamycins | 1 | 2023 | 1 | 0.780 |
Why?
|
| Female | 25 | 2026 | 12715 | 0.780 |
Why?
|
| Opportunistic Infections | 1 | 2023 | 7 | 0.770 |
Why?
|
| Communicable Diseases | 1 | 2023 | 15 | 0.760 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2021 | 2 | 0.700 |
Why?
|
| Pseudomonas Infections | 1 | 2021 | 2 | 0.700 |
Why?
|
| Mass Screening | 2 | 2026 | 693 | 0.670 |
Why?
|
| Adult | 21 | 2026 | 7621 | 0.670 |
Why?
|
| Middle Aged | 19 | 2026 | 7954 | 0.650 |
Why?
|
| California | 9 | 2026 | 2433 | 0.610 |
Why?
|
| Herpes Zoster Vaccine | 3 | 2025 | 62 | 0.590 |
Why?
|
| Retinal Vasculitis | 3 | 2014 | 3 | 0.570 |
Why?
|
| Herpes Zoster | 3 | 2025 | 82 | 0.570 |
Why?
|
| Rheumatic Diseases | 1 | 2015 | 1 | 0.460 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 27 | 0.450 |
Why?
|
| Cohort Studies | 9 | 2025 | 2502 | 0.440 |
Why?
|
| Disease Management | 1 | 2015 | 110 | 0.430 |
Why?
|
| Health Care Surveys | 1 | 2015 | 210 | 0.430 |
Why?
|
| Outpatients | 1 | 2015 | 103 | 0.430 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 193 | 0.420 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 168 | 0.420 |
Why?
|
| Visual Acuity | 2 | 2014 | 19 | 0.400 |
Why?
|
| Disinfection | 1 | 2013 | 1 | 0.400 |
Why?
|
| Skin Diseases, Infectious | 1 | 2013 | 1 | 0.400 |
Why?
|
| Ethambutol | 2 | 2023 | 2 | 0.400 |
Why?
|
| Soft Tissue Infections | 1 | 2013 | 6 | 0.400 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 15 | 0.400 |
Why?
|
| Case-Control Studies | 4 | 2024 | 1107 | 0.370 |
Why?
|
| Adolescent | 12 | 2026 | 3625 | 0.360 |
Why?
|
| Young Adult | 10 | 2026 | 2538 | 0.350 |
Why?
|
| Respiratory Tract Infections | 2 | 2026 | 59 | 0.340 |
Why?
|
| Rifampin | 2 | 2023 | 3 | 0.310 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 1157 | 0.310 |
Why?
|
| Lung | 2 | 2023 | 57 | 0.300 |
Why?
|
| Risk Factors | 5 | 2025 | 3291 | 0.300 |
Why?
|
| Seasons | 2 | 2024 | 116 | 0.270 |
Why?
|
| Prospective Studies | 4 | 2023 | 1251 | 0.250 |
Why?
|
| Treatment Outcome | 5 | 2023 | 1161 | 0.250 |
Why?
|
| Incidence | 3 | 2026 | 1278 | 0.240 |
Why?
|
| Metapneumovirus | 1 | 2026 | 7 | 0.240 |
Why?
|
| Paramyxoviridae Infections | 1 | 2026 | 8 | 0.240 |
Why?
|
| Health Resources | 1 | 2026 | 39 | 0.240 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2025 | 23 | 0.230 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2026 | 37 | 0.230 |
Why?
|
| Regional Health Planning | 1 | 2025 | 6 | 0.230 |
Why?
|
| Tuberculosis | 1 | 2025 | 23 | 0.220 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 18 | 0.220 |
Why?
|
| Recurrence | 1 | 2024 | 166 | 0.210 |
Why?
|
| Corneal Transplantation | 1 | 2024 | 1 | 0.210 |
Why?
|
| Corneal Diseases | 1 | 2024 | 3 | 0.210 |
Why?
|
| Clarithromycin | 1 | 2023 | 1 | 0.210 |
Why?
|
| Rifabutin | 1 | 2023 | 1 | 0.210 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2024 | 12 | 0.210 |
Why?
|
| Azithromycin | 1 | 2023 | 3 | 0.210 |
Why?
|
| Societies, Medical | 1 | 2023 | 71 | 0.200 |
Why?
|
| Amikacin | 1 | 2023 | 1 | 0.200 |
Why?
|
| Macrolides | 1 | 2023 | 6 | 0.190 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2023 | 16 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2026 | 380 | 0.180 |
Why?
|
| Odds Ratio | 1 | 2024 | 631 | 0.180 |
Why?
|
| Electronic Health Records | 2 | 2025 | 719 | 0.180 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2021 | 1 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 1 | 2023 | 319 | 0.170 |
Why?
|
| Rheumatology | 1 | 2021 | 3 | 0.170 |
Why?
|
| Sex Factors | 2 | 2019 | 599 | 0.150 |
Why?
|
| Immunosuppressive Agents | 2 | 2014 | 17 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 120 | 0.120 |
Why?
|
| Oregon | 3 | 2024 | 172 | 0.110 |
Why?
|
| Linezolid | 1 | 2015 | 1 | 0.110 |
Why?
|
| Drug Tolerance | 1 | 2015 | 2 | 0.110 |
Why?
|
| Vaccines, Synthetic | 2 | 2025 | 40 | 0.110 |
Why?
|
| Minocycline | 1 | 2014 | 1 | 0.110 |
Why?
|
| Ofloxacin | 1 | 2014 | 1 | 0.110 |
Why?
|
| Granuloma Annulare | 1 | 2014 | 1 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2015 | 1455 | 0.110 |
Why?
|
| Child | 4 | 2015 | 2485 | 0.110 |
Why?
|
| Prognosis | 2 | 2014 | 609 | 0.110 |
Why?
|
| Epiretinal Membrane | 1 | 2014 | 1 | 0.100 |
Why?
|
| Retinal Hemorrhage | 1 | 2014 | 2 | 0.100 |
Why?
|
| Retinal Neovascularization | 1 | 2014 | 2 | 0.100 |
Why?
|
| Carrier State | 1 | 2013 | 8 | 0.100 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 6 | 0.100 |
Why?
|
| Cross Infection | 1 | 2013 | 24 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2013 | 50 | 0.100 |
Why?
|
| Herpesvirus 3, Human | 2 | 2024 | 42 | 0.100 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2012 | 1 | 0.100 |
Why?
|
| Drainage | 1 | 2012 | 2 | 0.100 |
Why?
|
| Stents | 1 | 2012 | 5 | 0.100 |
Why?
|
| Optic Neuritis | 1 | 2012 | 3 | 0.090 |
Why?
|
| Pancreatic Ducts | 1 | 2012 | 6 | 0.090 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2012 | 8 | 0.090 |
Why?
|
| Antirheumatic Agents | 1 | 2012 | 12 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 27 | 0.090 |
Why?
|
| Systemic Vasculitis | 1 | 2011 | 1 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1295 | 0.090 |
Why?
|
| Gonadal Hormones | 1 | 2011 | 1 | 0.090 |
Why?
|
| Octodon | 1 | 2011 | 1 | 0.090 |
Why?
|
| HIV Infections | 1 | 2017 | 584 | 0.090 |
Why?
|
| Sexual Maturation | 1 | 2011 | 8 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 16 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 702 | 0.080 |
Why?
|
| Pandemics | 2 | 2024 | 295 | 0.080 |
Why?
|
| Time Factors | 3 | 2016 | 1038 | 0.070 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2026 | 26 | 0.060 |
Why?
|
| Length of Stay | 1 | 2026 | 182 | 0.060 |
Why?
|
| Datasets as Topic | 1 | 2025 | 19 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2026 | 105 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2015 | 84 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 99 | 0.050 |
Why?
|
| Immunoglobulin G | 2 | 2016 | 35 | 0.050 |
Why?
|
| Universities | 1 | 2024 | 11 | 0.050 |
Why?
|
| China | 1 | 2024 | 132 | 0.050 |
Why?
|
| Vaccines, Combined | 1 | 2024 | 81 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2024 | 87 | 0.050 |
Why?
|
| Public Health | 1 | 2024 | 84 | 0.050 |
Why?
|
| Animals | 2 | 2016 | 285 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2023 | 72 | 0.050 |
Why?
|
| Masks | 1 | 2021 | 5 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 142 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 110 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 179 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2016 | 3 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 5 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2016 | 4 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 19 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 9 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 23 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2016 | 34 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 30 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 80 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 874 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 122 | 0.030 |
Why?
|
| Remission Induction | 1 | 2014 | 26 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 215 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 228 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 2014 | 7 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 6 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2014 | 15 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 23 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 398 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 4 | 0.020 |
Why?
|
| Etanercept | 1 | 2012 | 4 | 0.020 |
Why?
|
| Adalimumab | 1 | 2012 | 4 | 0.020 |
Why?
|
| Infliximab | 1 | 2012 | 6 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 446 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 29 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 25 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 420 | 0.020 |
Why?
|
| Running | 1 | 2011 | 3 | 0.020 |
Why?
|
| Sexual Development | 1 | 2011 | 3 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2011 | 6 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 304 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 227 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 866 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 1093 | 0.020 |
Why?
|
Concepts
(179)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(6)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->